Redeye provides a preview of its Q4'21 estimates for BONESUPPORT ahead of its report next week. We believe the quarter will set another record in sales, but due to omicron's impact in the last weeks of 2021, we make some slight downwards adjustments to our previous estimates. We expect the report to help reignite interest for this severely beaten share and the expected FDA approval before the end of the month to boost further interest for this exciting growth story.
LÄS MER
